Ocugen, Inc. - Common Stock (OCGN)

Canaccord has a $12 price target on the stock, representing a potential upside of about 415% from the stock’s closing price on Monday.

Ocugen (OCGN) Q4 2025 Earnings Call Transcript

Ocugen said that it intends to start seeking the approval of the FDA for its experimental therapy OCU400 starting this year.

Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positive market sentiment.

Stargardt disease is a form of inherited macular degeneration, affecting more than 100,000 people in the U.S. and Europe combined.

Ocugen (OCGN) Q3 2025 Earnings Call Transcript

Ocugen reports Q3 2025 results with a major revenue beat and updates on its late-stage gene therapy pipeline for blindness diseases.

A peer across the Pacific Ocean has purchased the rights to one of the biotech's pipeline drugs.

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the exclusive Korean rights to OCU400.

Ocugen Inc (OCGN) reports Q2 2025 earnings with $1.37M revenue, beating estimates by 284%, while EPS loss narrows to -$0.05. Progress in gene therapy trials boosts investor optimism.

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidiary OrthoCellix with Carisma Therapeutics.

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help patients who currently have no other options.